The results indicated that cGAMP@dual-anti-Exos presented excellent targeting and anti-tumor effects, since PLGVA peptides could be cut off by the matrix metalloproteinase enzyme (MMP-2) inside the TME, and anti-PD-L1 was separated from Exos to achieve ICB (137). The gene discussed is CD274; the disease is neoplasm.